How-To Guide
How to Use AI for a Psychiatry Practice in 2026: Intake, Med Management, Risk Assessment & Telepsych
Published May 18, 2026 · 16 min read · For psychiatrist-owners of 1-5 MD outpatient psychiatry practices — adult, child & adolescent, addiction, geriatric, telepsychiatry, and integrated-care models.
TL;DR
- Two AI layers for a psychiatry practice in 2026: a clinical documentation layer (ambient scribing, med reconciliation, PDMP integration, risk-assessment pre-population) and a patient-and-ops layer (intake, prior auth, scheduling, recall, treatment summary letters).
- Ten prompts below: new-patient intake, initial psychiatric eval SOAP, med management follow-up, C-SSRS and safety-plan drafter, PDMP query summary, prior-auth letter, stimulant/benzodiazepine risk-mitigation plan, telepsych workflow memo, collateral release and treatment summary, owner monthly scorecard.
- AI drafts; the psychiatrist certifies. Every risk assessment, every controlled-substance prescription, and every diagnosis change gets clinician-signed before it touches the chart.
- PHI and SUD records (42 CFR Part 2) go only into BAA-covered tools — never consumer ChatGPT. State AI-use consent (CA AB 3030, TX SB 815, UT HB 452, IL HB 1806) belongs in the intake packet.
- ROI is real: a solo psychiatrist recaptures 8-12 hours a week — equivalent to 12-20 extra appointments or a real life outside of work.
The 2026 psychiatry practice AI stack
| Layer | Tool | Use |
|---|---|---|
| EHR + psychiatry module | Osmind, Valant, SimplePractice, TherapyNotes, Alma, Headway, Oracle Cerner Behavioral Health, Epic Behavioral Health, athenaOne Behavioral Health, ICANotes, eClinicalWorks Behavioral | Charting, scheduling, billing, telehealth |
| Ambient scribe | Heidi, Abridge, DeepScribe, Suki Assistant, Nuance DAX Copilot, Freed, Sunoh.ai, Nabla, Augmedix | Psychiatric SOAP, therapy notes, med management |
| EPCS + PDMP | DrFirst Rcopia + iPrescribe, Surescripts EPCS, Appriss Health NarxCare, Bamboo Health PMP Gateway, state PDMPs (CA CURES, TX PMP, FL E-FORCSE, NY I-STOP, OH OARRS) | Controlled-substance e-prescribing, PDMP query, red-flag screen |
| Measurement-based care | Owl Health (Owl Practice), Mirah, Greenspace, Blueprint Health, NeuroFlow, Osmind Measurement, Valant Measurement | PHQ-9, GAD-7, C-SSRS, AUDIT, DAST, outcomes tracking |
| Digital therapeutic + monitoring | Rejoyn (MDD FDA), EndeavorRx (pediatric ADHD FDA), reSET / reSET-O (SUD FDA), Woebot Health, Talkspace AI, Spring Health, Lyra, Big Health (Sleepio, Daylight), Headspace, Calm Health | Adjunct care, between-visit engagement, sleep/anxiety |
| Writing + ops | Happycapy Pro, Claude for Work, Copilot in a BAA tenant | Patient letters, marketing, SOPs, staff training |
Happycapy Pro lives in the writing-and-ops layer. You use it for patient communications (after redaction), marketing copy, newsletters, SOPs, and staff training. Happycapy Pro is $20/month — a small line item vs what an ambient-scribe or EHR seat costs, but it covers the entire writing side of the practice.
10 prompts a psychiatry practice should keep in 2026
1. New-patient intake synthesis
You are my psychiatric intake coordinator. Below is the intake packet (de-identified — patient as "PT"), including chief complaint, symptom onset, current meds, prior psychiatric treatment, SUD history, medical history, family history, developmental history (if applicable), legal history, social history, PHQ-9, GAD-7, AUDIT, DAST, C-SSRS.
Produce an intake synthesis for the psychiatrist before the first visit:
1. Chief complaint and presenting concerns in one paragraph.
2. Current symptom severity by scale with clinical cutoffs (PHQ-9, GAD-7, AUDIT, DAST, PSS, ACE).
3. Risk flags: C-SSRS positive item, recent hospitalization, self-harm, violence history, access to firearms, SI plan/intent, protective factors.
4. Medication reconciliation: every current psychotropic and non-psychotropic med with dose, schedule, duration, prescriber, perceived benefit/side effect. Flag drug-drug and drug-disease interactions.
5. SUD screen: every substance with frequency, route, duration, last use, prior treatment, current readiness (Stages of Change).
6. Prior diagnoses with dates and evidence; any likely differential to consider.
7. Psychotherapy history: modality, frequency, duration, outcome.
8. Social determinants: housing, employment, relationships, legal, financial, cultural.
9. Questions to ask during the initial evaluation, prioritized.
10. Administrative: insurance eligibility, prior-auth requirements, release-of-information needs, collateral contacts.
Do not make diagnostic pronouncements. Do not recommend medications. The psychiatrist will evaluate and decide.
2. Initial psychiatric evaluation SOAP
Below is the ambient-scribe transcript of a 60-minute initial psychiatric evaluation on PT_CODE. The psychiatrist's dictated plan is at the end.
Produce a psychiatric evaluation SOAP:
1. Identifying data: age, sex, occupation, living situation, referral source.
2. Chief complaint (direct quote).
3. History of present illness: onset, course, severity, precipitants, associated symptoms, prior treatment.
4. Past psychiatric history: prior diagnoses, hospitalizations, suicide attempts, psychotherapy, medication trials with response.
5. Substance use history: each substance with pattern, last use, treatment history, withdrawal history.
6. Medical history: chronic conditions, current meds, surgeries, allergies.
7. Family psychiatric history.
8. Developmental history (if child/adolescent): milestones, school, peer relationships, legal.
9. Social history: relationships, work, finances, legal, trauma, spirituality.
10. Mental status examination: appearance, behavior, speech, mood, affect, thought process, thought content (SI/HI explicit), perception, cognition, insight, judgment.
11. Assessment: differential diagnosis with reasoning, severity, functional impact.
12. Risk assessment: C-SSRS result, protective factors, acute vs chronic risk.
13. Plan: medication decisions (start/continue/adjust/discontinue), psychotherapy, safety plan, labs, follow-up interval, collateral contacts, releases, emergency plan.
14. CPT code: 90792 (psychiatric diagnostic eval with medical services) and any add-ons (interactive complexity 90785, prolonged service 99354-99355 or 99417).
Flag for the psychiatrist any item pulled from the transcript that feels uncertain. The psychiatrist signs.
3. Med management follow-up SOAP
Below is the ambient-scribe transcript of a 20-30 minute med management follow-up on PT_CODE. Current med list, prior session notes, and measurement-based care scores attached.
Produce a med management SOAP:
1. Interval history since last visit: symptoms, response to current regimen, side effects, missed doses, new stressors, substance use, sleep, appetite, energy, concentration, libido.
2. Measurement-based care: PHQ-9, GAD-7, PCL-5, YMRS, ASRS, AUDIT, DAST, C-SSRS — with comparison to baseline and last visit.
3. Mental status exam (focused).
4. Medication review: each psychotropic with dose, compliance, response, side effects, labs due (lithium level, valproate level, metabolic panel, lipid panel for antipsychotics, TSH, CBC).
5. Risk assessment: C-SSRS result, protective factors, any new risk flags.
6. Assessment: diagnosis confirmed/revised, response category (remission/response/partial response/non-response), side-effect burden.
7. Plan: medication decision with dose, frequency, duration, and patient education; labs ordered; psychotherapy status; between-visit monitoring plan (Mirah, Owl, Greenspace, Blueprint); next appointment.
8. Controlled-substance notes if applicable: PDMP queried with date, prescription details, signed compliance notes.
9. CPT code: 99212-99215 (E&M level based on MDM) + 90833/90836/90838 (add-on psychotherapy if provided) or 90832/90834/90837 (stand-alone psychotherapy).
Flag anything the psychiatrist should double-check. The psychiatrist signs.
4. C-SSRS and safety plan drafter
PT_CODE screened positive on C-SSRS today. Here is the screen result, the interview transcript, current meds, recent PHQ-9 item 9, prior suicide attempts (if any), access to lethal means, and social supports.
Produce two documents:
A. C-SSRS structured documentation:
1. C-SSRS domains (ideation, intensity, behavior) with specific items endorsed.
2. Timeline: lifetime, past 12 months, past 30 days, since last visit.
3. Static risk factors (history, demographics, diagnosis, family history).
4. Dynamic risk factors (current symptoms, acute stressors, substance use, sleep, agitation).
5. Protective factors (reasons for living, social support, treatment engagement, religious/cultural).
6. Risk stratification: low/moderate/high (acute) and low/moderate/high (chronic).
7. Clinical reasoning for the stratification in two sentences.
B. Stanley-Brown Safety Plan:
1. Warning signs (thoughts, images, moods, situations, behavior).
2. Internal coping strategies.
3. Social contacts and settings that distract.
4. People I can ask for help (phone numbers).
5. Professionals or agencies (therapist, psychiatrist, crisis line 988, ED address).
6. Means restriction: specific plan for firearms, medications, other means — with who is holding them.
7. Reasons for living.
The psychiatrist reviews every item, modifies as needed, and signs. Crisis dispositions (ED transfer, 72-hour hold) are clinical decisions, not AI outputs.
5. PDMP query summary
Below is the PDMP report for PT_CODE from [STATE_PDMP] for the past 24 months. Includes every controlled-substance prescription, prescriber, pharmacy, date, quantity, days supply, and refills.
Produce a PDMP summary for the chart:
1. Opioid MME summary: current daily MME, peak MME, any dose escalations.
2. Benzodiazepine summary: diazepam equivalents, any overlap with opioids.
3. Stimulant summary: Schedule II stimulants, any concurrent overlap.
4. Z-drug and gabapentinoid summary (if applicable).
5. Prescriber count in past 6 and 12 months; pharmacy count in past 6 and 12 months.
6. Red-flag patterns: multiple prescribers, multiple pharmacies, early refills, overlapping prescriptions of the same class, opioid + benzodiazepine overlap, opioid + stimulant, history of ER visits for overdose (if available).
7. CDC 2022 opioid prescribing guideline flags: daily MME over 50 or 90, co-prescription with benzos, >7-day supply for acute pain.
8. Summary to include in today's note: "PDMP queried on DATE; findings: ..."
9. Narcan co-prescription consideration under the SUPPORT Act and state laws.
The psychiatrist reviews before any controlled-substance prescription is signed. Every Schedule II-V prescription gets EPCS with two-factor auth.
6. Prior-authorization letter
PT_CODE needs prior authorization for MEDICATION (e.g., Spravato / esketamine, Caplyta / lumateperone, Vraylar / cariprazine, brand-name SSRI, non-formulary stimulant, buprenorphine product, long-acting injectable antipsychotic).
Draft a prior-auth letter:
1. Patient identification, insurance, diagnosis (ICD-10 with specifier).
2. Medication requested with strength, dose, and duration.
3. Clinical indication with diagnosis-to-FDA-label alignment (or the off-label rationale with supporting guidelines — APA, CANMAT, WFSBP, CINP).
4. Prior trials: every medication previously tried, dose, duration, outcome (response/partial/non-response), reason for discontinuation (tolerability/inefficacy).
5. Current severity and functional impact (measurement-based care scores).
6. Why step therapy is not appropriate (medical exception, prior failure, contraindication, patient safety).
7. Monitoring plan and follow-up interval.
8. References to clinical guidelines and FDA label.
9. Signature block for psychiatrist (NPI, DEA if controlled).
The psychiatrist reviews and signs. If denied, the appeal path includes peer-to-peer review, state DOI complaint, ERISA appeal if applicable, and state utilization review.
7. Stimulant/benzodiazepine risk-mitigation plan
PT_CODE is on a Schedule II stimulant (methylphenidate, amphetamine, lisdexamfetamine) or a benzodiazepine (clonazepam, lorazepam, alprazolam, diazepam) with a chronic indication. Review and document the risk-mitigation plan for today's visit.
Produce a controlled-substance risk-mitigation memo:
1. Diagnosis, medication, dose, duration, response, side effects.
2. PDMP query date and findings summary.
3. Informed consent on controlled-substance use, including diversion risk, dependence, withdrawal, driving, pregnancy, breastfeeding, interaction with alcohol and other CNS depressants.
4. Controlled-substance agreement status: signed on file, last review date, any violations.
5. Urine drug screen results if obtained, frequency, any unexpected findings.
6. Tolerance and dose-escalation review: any upward pressure, clinical reason, adherence to state day-supply limits.
7. Co-prescription review: opioid + benzodiazepine combination (CDC 2022 caution), stimulant + SSRI interaction, stimulant + MAOI contraindication.
8. Taper plan if appropriate (deprescribing candidate).
9. CDC and APA guidelines referenced.
10. Plan: continue, adjust, taper, refer to SUD treatment, add naloxone co-prescription if opioid overlap.
The psychiatrist reviews and signs every controlled-substance prescription. AI never writes the prescription — only the supporting note.
8. Telepsychiatry workflow memo
Draft the weekly telepsych workflow memo for our practice (we see patients in STATES_LIST via telepsych).
Cover:
1. State licensure: every state where we see a patient requires a medical license there (or interstate compact IMLC if eligible, or a telehealth registration program where available).
2. DEA Telemedicine Rule updates for 2026: currently, buprenorphine for OUD and Schedule III-V prescribing by telemedicine may require an initial in-person or a prior provider relationship under the DEA's proposed rule — track the final rule that succeeds the COVID-era flexibilities (extended through end of 2025).
3. Ryan Haight Act special registration status.
4. State-specific rules: CA (telehealth in-state license + AB 1241/AB 457 controls on out-of-state), NY (telehealth location requirements), TX (TMB telemedicine rules), FL (board rules), IL/NJ/PA/OH variations.
5. Privacy and platform: HIPAA-compliant platform with BAA (doxy.me, SimplePractice, Osmind, Zoom for Healthcare, Epic MyChart, Doximity Dialer).
6. Emergency plan: address of each patient verified each visit, local 911 and nearest ED, safety planning for patients in high-risk states.
7. Informed consent for telehealth: state-specific disclosures.
8. Technical failure backup: phone-only billing codes, documentation of connection issues.
The psychiatrist-owner certifies the annual compliance review. Every telepsych session documents patient location and emergency contact.
9. Collateral release and treatment summary
PT_CODE requests a treatment summary for RECIPIENT (e.g., PCP, therapist, school, employer, court, disability carrier, insurance, family member). Release-of-information form signed and scoped to RECIPIENT_SCOPE. Part 2 (SUD) disclosure status: [YES/NO].
Draft a treatment summary letter:
1. Date, recipient, patient identifier (scoped to the ROI).
2. Purpose of the letter (direct quote from ROI).
3. Dates of treatment, frequency, modality.
4. Current diagnoses with ICD-10 (scope-limited to what the ROI authorizes).
5. Current medications (only if ROI includes medication disclosure).
6. Functional status and treatment response in plain language.
7. Recommendations as they pertain to the recipient's role (school accommodations, work accommodations, court-related observations framed carefully, disability-carrier functional descriptions).
8. 42 CFR Part 2 re-disclosure notice if any SUD content is disclosed.
9. Clinician signature, NPI, license number, contact info.
Redact anything outside the ROI scope. SUD content requires Part 2-compliant specific authorization. Court-ordered disclosures require counsel review before release. The psychiatrist certifies.
10. Psychiatrist-owner monthly scorecard
Below is the de-identified monthly dashboard: patient panel, visit volume, payer mix, revenue, no-shows, measurement-based care compliance, risk events.
Produce a psychiatrist-owner one-page monthly scorecard:
1. Panel size and capacity utilization (total active patients, new starts, graduations, terminations).
2. Visit volume: initial evaluations, med management, psychotherapy, telepsych vs in-person.
3. Payer mix and collection rate by payer; commercial, Medicare, Medicaid, self-pay, OON.
4. Revenue vs budget; revenue per visit; collections aging.
5. No-show and late-cancel rate by payer and day of week.
6. Measurement-based care completion rate (PHQ-9, GAD-7, C-SSRS) and outcomes trend.
7. Risk events: hospitalizations, ED visits, safety events, controlled-substance diversions, AMA terminations, board complaints, malpractice notices.
8. Compliance: EPCS + PDMP query rate, controlled-substance agreement currency, MATE Act training, state CME, license renewals, BAA inventory.
9. Team: clinician burnout signals, ambient-scribe adoption, note-closure time.
10. One "focus for next month" sentence.
Keep it under one page. Use patient codes, not names. No PHI.
Compliance floor — don't skip
- HIPAA 45 CFR 160/164 + 42 CFR Part 2. PHI requires BAA. SUD records get a stricter standard — Part 2 specific authorization, redisclosure prohibition, and careful handling of ambient transcripts that include substance-use content. The 2024 Part 2 final rule aligns more with HIPAA but special rules still apply.
- State AI-use and AI-scribe consent. CA AB 3030 (eff Jan 2025), TX SB 815 (eff Sep 2025), UT HB 452, IL HB 1806 (eff Jan 2026), NY S1331A pending. Put the disclosure in the intake packet, not as a mid-session pop-up.
- DEA EPCS + PDMP. SUPPORT Act 2017 + 21 CFR 1306 + state PDMP mandates (all 50 states). Every Schedule II-V prescription is electronic with two-factor auth. PDMP queried per state rules (usually every controlled-substance prescription, with exceptions for hospice, initial 3-day acute pain, etc.). MATE Act 8-hour training required for DEA registration renewals since June 2023.
- CDC 2022 opioid prescribing guideline. Psychiatrists who prescribe opioids (rare but it happens for atypical indications) follow CDC 2022, naloxone co-prescription, state-specific day-supply limits, PDMP, and risk-mitigation.
- Telehealth state licensure. Every state where a patient is located requires a medical license there (or IMLC, or a telehealth registration where available). Track DEA Telemedicine Rule updates for controlled-substance prescribing by telemedicine. The COVID flexibilities ended; the DEA's proposed rule for ongoing telemedicine controlled-substance prescribing is in final-rule process.
- Duty to warn / Tarasoff. Every state has a version (duty to warn, duty to protect, or permissive disclosure). AI-drafted risk assessments never override the clinical decision to break confidentiality when Tarasoff applies.
- FTC Endorsement Guides 2023 + Fake Reviews Rule 16 CFR 465. Testimonials, patient stories, and reviews follow FTC guidance — no fake reviews, material-connection disclosures, typicality language. $51,744/violation FY 2026.
- Measurement-based care + MIPS MVP. CMS Advancing Care for Behavioral Health MVP 2025. PHQ-9 and GAD-7 for adults; PSC-17 and CRAFFT for adolescents.
A 60-day rollout for a solo or 2-3 psychiatrist practice
Days 1-20. Pick one ambient-scribe tool with a BAA (Heidi, Abridge, DeepScribe, Suki, Nuance DAX Copilot, Freed, Sunoh.ai) and one writing tool (Happycapy Pro, Claude for Work). Add the AI-use disclosure to your intake packet per state law. Sign BAAs. Document the vendor-risk review for your compliance binder.
Days 21-40. Roll out prompts 2, 3, and 5 (initial eval SOAP, med management SOAP, PDMP summary). These deliver the biggest daily time savings — 15-30 minutes per initial eval and 5-10 minutes per med check. Measure note-closure time before and after.
Days 41-60. Add prompts 1, 4, 6-10 (intake, C-SSRS and safety plan, prior auth, controlled-substance risk mitigation, telepsych workflow, treatment summary, owner scorecard). Hold a weekly 15-minute AI retro: what broke, what saved time, what the psychiatrist had to rewrite. If you are not saving 8-12 hours a week of after-hours charting by day 60, something is wrong with the prompts or the EHR integration.
Common mistakes psychiatry practices make with AI
- Using consumer ChatGPT for patient documentation. PHI + 42 CFR Part 2 violation. BAA-covered tools only.
- Letting AI sign risk assessments. Every C-SSRS, every safety plan, every disposition decision is clinician-signed.
- Ambient scribing without consent. State AI-use laws are explicit. The consent belongs in the intake.
- Skipping PDMP queries because the AI said no controlled substances changed. The PDMP query is on you, every time.
- Telepsych without verifying state licensure. Every state the patient is in requires a license there, or the interstate compact.
Frequently asked questions
Can I use ambient-scribe AI during a psychotherapy session?
Only with explicit patient consent, a signed BAA with the vendor, and careful handling of substance-use content. 42 CFR Part 2 imposes a higher standard than HIPAA for SUD records — ambient transcripts that capture substance-use history need the same special protection. Most psychiatric ambient tools (Heidi, Abridge, DeepScribe, Suki, Nuance DAX Copilot, Freed, Sunoh.ai) now support a mental-health profile with BAA and Part 2 attestation. California AB 3030 (eff Jan 2025) requires notice when generative AI is used in clinical communication. Texas SB 815, Utah HB 452, and Illinois HB 1806 have similar rules. Put the consent in the intake, not as a pop-up mid-session.
Will AI replace psychiatrists?
No. AI is genuinely useful for documentation (SOAP, med reconciliation, treatment summaries), patient-facing scheduling, and operational load. It is not a substitute for diagnostic judgment, therapeutic alliance, risk assessment, or the prescribing decision. FDA has cleared some digital therapeutics (Rejoyn for MDD, EndeavorRx for pediatric ADHD) but these are adjuncts under a prescriber's supervision — not replacements. The psychiatrists who are winning in 2026 use AI to recapture 10-15 hours a week that used to go to after-hours notes and prior auths.
What is the DEA EPCS and PDMP workflow with AI?
All states now mandate EPCS for controlled substances (SUPPORT Act 2017 rolled out through 2023 with state extensions). Every state has a PDMP (prescription drug monitoring program) — CA CURES, TX PMP, FL E-FORCSE, NY I-STOP, OH OARRS, etc. AI can pull and summarize a PDMP query, flag red-flag patterns (multiple prescribers, multiple pharmacies, early refills, dangerous combinations), and draft a note for the chart. AI does not make the prescribing decision. The MATE Act 8-hour training requirement (DEA registration renewal since June 2023) applies to every prescriber.
Is AI safe for suicide and violence risk assessment?
Only as a drafting and structure aid. Structured tools (Columbia Suicide Severity Rating Scale C-SSRS, PHQ-9 item 9, HCR-20, VRAG, START) still drive the clinical decision. AI can pre-populate the structured assessment, flag red-flag language from the intake, cross-reference prior records, and draft the safety plan. The clinical judgment — hospitalize, outpatient with safety plan, increase contact frequency, involve collateral — belongs to the psychiatrist. Malpractice carriers are explicit: AI-drafted risk assessments without a clinician-signed note will not be defended.
Does AI pay off in a 1-3 psychiatrist practice?
Yes, and quickly. A solo psychiatrist who spent 10-15 hours a week on after-hours notes, prior auths, and PDMP queries recaptures 70-80% of that with ambient scribing + prior-auth automation + PDMP integration. That is 8-12 hours back per week. For a psychiatrist billing $400-700 per evaluation and $200-350 per med check, that time converts to 12-20 additional appointments a week or a real life outside of work. The ambient-scribe stack runs $100-300/month; the rest of the tooling is usually inside the EHR.
Sources & further reading
- HIPAA 45 CFR 160 + 164 + BAA + §164.514 de-identification; 42 CFR Part 2 (2024 final rule)
- DEA EPCS (SUPPORT Act 2017, 21 CFR 1306) + Ryan Haight Act + DEA Telemedicine Rule (proposed final rule for post-COVID telemedicine controlled-substance prescribing)
- MATE Act 8-hour training + CDC 2022 Clinical Practice Guideline for Prescribing Opioids for Pain
- State AI-use + AI-scribe consent: CA AB 3030 (eff Jan 2025), TX SB 815 (eff Sep 2025), UT HB 452, IL HB 1806 (eff Jan 2026), NY S1331A pending
- APA Practice Guidelines (MDD, bipolar, schizophrenia, OUD, SUD) + Columbia Suicide Severity Rating Scale (C-SSRS) + Stanley-Brown Safety Plan
- State PDMPs: CA CURES, TX PMP, FL E-FORCSE, NY I-STOP, OH OARRS, IL PMP, PA PDMP, GA PDMP, AZ CSPMP, MI MAPS, WA PMP, OR PDMP, CO PDMP, NJ NJPMP, VA PMP, NC CSRS
- CMS MIPS MVP Advancing Care for Behavioral Health + Medicare behavioral health CPT 90791, 90792, 90832, 90834, 90837, 90833, 90836, 90838, 99211-99215, 99492-99494 (CoCM)
- FTC Endorsement Guides 2023 + Fake Reviews Rule 16 CFR 465 + state truth-in-advertising